Harbin Gloria Pharmaceuticals Co., Ltd

Shenzhen Stock Exchange 002437.SZ

Harbin Gloria Pharmaceuticals Co., Ltd Debt to Equity Ratio for the year ending December 31, 2023: 0.41

Harbin Gloria Pharmaceuticals Co., Ltd Debt to Equity Ratio is 0.41 for the year ending December 31, 2023, a -54.41% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Harbin Gloria Pharmaceuticals Co., Ltd Debt to Equity Ratio for the year ending December 31, 2022 was 0.89, a 8.43% change year over year.
Harbin Gloria Pharmaceuticals Co., Ltd Debt to Equity Ratio for the year ending December 31, 2021 was 0.82, a 12.29% change year over year.
Harbin Gloria Pharmaceuticals Co., Ltd Debt to Equity Ratio for the year ending December 31, 2020 was 0.73, a -58.38% change year over year.
Harbin Gloria Pharmaceuticals Co., Ltd Debt to Equity Ratio for the year ending December 31, 2019 was 1.76, a 143.93% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Shenzhen Stock Exchange: 002437.SZ

Harbin Gloria Pharmaceuticals Co., Ltd

CEO	Mr. Leifeng Guo
IPO Date	Oct. 27, 2011
Location	China
Headquarters	No. 29, Beijing Road
Employees	3,085
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. It offers cardiac cerebrovascular medication, skeletal muscle system, vitamins and minerals, urinary system medication, antitumor medication, endocrine medicine, anti-infective drugs, respiratory medication, antihistamine, peptic, and other products. Harbin Gloria Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Harbin, the People's Republic of China.

Key trends

Past 5 years